Whalesbook
Strategic Analysis & Impact
AstraZeneca Pharma India Limited has recently received an Environmental, Social, and Governance (ESG) rating of 70 for the fiscal year 2024-25 from NSE Sustainability Ratings & Analytics Limited. This rating, which places the company in the 'Strong' category according to SEBI guidelines for ESG providers (scores 61-70 indicate 'Strong'), is significant as it was independently prepared and unsolicited by the company. This means NSE Sustainability utilized publicly available information to assess AstraZeneca India's performance across environmental, social, and governance factors.
What is ESG?
ESG stands for Environmental, Social, and Governance.
- Environmental: How a company impacts nature – its carbon footprint, waste management, and resource usage.
- Social: How a company treats people – its employees, customers, suppliers, and the communities it operates in. This includes labor practices, diversity, and product safety.
- Governance: How a company is run – its board structure, executive pay, transparency, shareholder rights, and ethical conduct.
An ESG rating is increasingly crucial for investors, as it signals a company's long-term sustainability, risk management capabilities, and ethical standing. For the Indian pharmaceutical sector, which has been noted to be generally lagging global peers in ESG practices but showing improving focus, such a rating provides a benchmark. A score of 70 suggests a robust commitment that aligns with the growing investor demand for sustainable investments.
Financial Context
While this news focuses on ESG, AstraZeneca Pharma India has demonstrated strong revenue growth recently, with a 31% increase in revenue from operations in Q2 FY25 and 44% in Q3 FY25. However, FY25 saw a net profit decline of 28.3% year-on-year, and net profit margins fell to 6.7% from 12.5% in FY24, partly due to exceptional items like provisions for factory site exit costs.
Risks & Outlook
The unsolicited nature of the rating adds credibility, as it wasn't influenced by direct company engagement. The rating for FY2024-25 indicates a forward-looking assessment of the company's sustainability practices. While no direct governance red flags or regulatory penalties were found associated with this disclosure, the company has faced challenges historically, such as past aggressive delisting tactics from its parent company over a decade ago, and more recently, the surrender of its manufacturing license for the Bangalore site. These operational changes are distinct from governance issues, but investors will monitor how sustainability is integrated amidst strategic shifts.
The outlook suggests that a strong ESG score of 70 can enhance investor confidence and potentially attract more capital, especially from institutional investors prioritizing sustainability. For AstraZeneca India, maintaining and improving this rating will be key to demonstrating its commitment to responsible business practices beyond financial performance.
Peer Comparison
Within the Indian pharmaceutical landscape, ESG performance is gaining traction. Competitors like Cipla also have an ESG score of 70 (S&P Global CSA score). Sun Pharma's scores are around 68, and Dr. Reddy's has higher scores (78 on S&P, 70 on EcoVadis). With an average ESG score for Indian companies often in the 'Emerging' or 'Adequate' range, a 'Strong' rating of 70 positions AstraZeneca India competitively among its peers, especially as the sector collectively works to enhance its ESG maturity. The average ESG score for IT companies in India is 72, Cement at 69, and Metals at 68, indicating that AstraZeneca's score is comparable to leading industries, suggesting strong performance in sustainability within its sector.